WebSite > Sichuan Qingmu Pharmaceutical Co., Ltd.

Sichuan Qingmu Pharmaceutical Co., Ltd.

  • Company Name Sichuan Qingmu Pharmaceutical Co., Ltd.
  • Tel 028-87827187
  • Email sales@eastonpharma.cn
  • WebSite www.qingmupharm.com/
  • CB Index 60
  •       Sichuan Qingmu Pharmaceutical Co., Ltd. is a wholly owned subsidiary company of Chengdu Easton Biopharmaceuticals Co., Ltd. (Stock Code: 688513), which is mainly engaged in research, production and marketing of APIs, CMO/CDMO business of APIs & advanced intermediates are also welcome. Qingmu was established in 2011, with more than 30% of staffs in R&D unit, 16 products are commercialized till now. Our facility is fully designed and operated as per EU/US/Japan GMP and EHS requirements, QC lab is equipped with HPLC, GC and ICP-MS, GC-MS, Malvern particle sizer, XRD, TGA, DSC, etc., which leads to GMP certificates for 10 APIs, 3 J-MFs, 1 USDMF, 1 USVMF and 1 CEP, and more certificates are on the way. Advantages of R&D 1) Process design based on the concept of QbD & Green chemistry to strengthen in-process quality control and EHS compliance. 2) Comprehensive quality research system which can meet the registration requirements in both Chinese and main regulatory markets (Japan, USA, EU, etc.). 3) Experienced in patent challenging on polymorphism form and synthesis process of APIs. Advantages of facility 1) 16 production lines and 4 independent clean areas for regular APIs with reaction volume 50~5000L. 2) OEB-4 workshop equipped with 4 production lines and 1 clean area, reaction volume 20~1000L. 3) 3 special reaction production lines, equipped with devices which suitable for 6 dangerous processes: hydrogenation, oxidation, chlorination, sulfonation, diazotization, and alkylation. 4) Qualified to produce Schedule II Controlled Substance APIs, and 3 products have been filed for registration. 5) Cytotoxic oncology APIs workshop is under construction. 6) Reaction temperature: -100℃~250℃; Pressure range: 0~8MPa. CDMO successful cases: 1) One National Class 1 New drugs (NCE) had been approved in 2020, realizing commercial supply of API. 2) Process validation of one patent challenge project has been successfully completed, and ASMF to be filed in EU
Sichuan Qingmu Pharmaceutical Co., Ltd. Product List
  • Product Name Ubenimex
  • MF C16H24N2O4
  • CAS 58970-76-6
  •  
  •  
  • Product Name Rotigotine
  • MF C19H25NOS
  • CAS 99755-59-6
  •  
  • Product Name Apalutamide
  • MF C21H15F4N5O2S
  • CAS 956104-40-8
  •  
  • Product Name Dacomitinib
  • MF C24H25ClFN5O2
  • CAS 1110813-31-4
  •  
  •  
  • Product Name Afoxolaner
  • MF C26H17ClF9N3O3
  • CAS 1093861-60-9
  •  
  • Product Name Relugolix
  • MF C29H27F2N7O5S
  • CAS 737789-87-6
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Firocoxib
  • MF C17H20O5S
  • CAS 189954-96-9
  •  
  • Product Name Etoricoxib
  • MF C18H15ClN2O2S
  • CAS 202409-33-4
  •  
  •  
  •  
  • Product Name Silodosin
  • MF C25H32F3N3O4
  • CAS 160970-54-7
  •  
  • Product Name Aprepitant
  • MF C23H21F7N4O3
  • CAS 170729-80-3
  •  
  • Product Name Olanzapine
  • MF C17H20N4S
  • CAS 132539-06-1
  •  
  • Product Name Nilotinib HCL
  • MF C28H25ClF3N7O2
  • CAS 923288-90-8
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Lotilaner
  • MF C20H14Cl3F6N3O3S
  • CAS 1369852-71-0
  •  
  • Product Name Darolutamide
  • MF C19H19ClN6O2
  • CAS 1297538-32-9
  •  
  •  
  • Product Name Robenacoxib
  • MF C16H13F4NO2
  • CAS 220991-32-2
  •  
  •  
  • Product Name Fruquintinib
  • MF C21H19N3O5
  • CAS 1194506-26-7
  •  
  • Product Name Sarolaner
  • MF C23H18Cl2F4N2O5S
  • CAS 1398609-39-6
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name axitinib
  • MF C22H18N4OS
  • CAS 319460-85-0
  •  
  • Product Name Abemaciclib
  • MF C27H32F2N8
  • CAS 1231929-97-7
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •